BIODESIX INC — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Biodesix reported Q2 2026 revenue of $26.9M (34% YoY growth), with Diagnostic Testing revenue of $25.4M (+42%) driven by 20,900 tests (+38% volumes). Gross margin improved to 82% (+200 bps). Cash increased to $30.0M (+17% vs. March 2026, including $6.5M from at-the-market offering). Net loss was $7.3M (37% improvement); Adjusted EBITDA loss of $3.2M (56% improvement). FY 2026 guidance maintained at $108–114M revenue (25% growth midpoint). Company approaching Adjusted EBITDA profitability.
Why this rating
Strong organic growth (34% revenue, 38% test volumes) and margin expansion are material for a $19.6M market-cap diagnostic company. Operating leverage emerging; path to profitability credible. Cash runway ~11 months at current burn; ATM dilution offset by revenue trajectory. Execution risk remains but momentum is real.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.